Report cover image

Global Cancer Immunotherapy Market - Industry Trends and Forecast to 2031

Publisher Data Bridge Market Research
Published Dec 01, 2023
Length 596 Pages
SKU # DAABD18458896

Description

Global Cancer Immunotherapy Market - Industry Trends and Forecast to 2031


The global cancer immunotherapy market is expected to reach USD 231,338.41 million by 2031 from USD 83,575.21 million in 2023, growing at a CAGR of 14.5% during the forecast period of 2024 to 2031.
Market Segmentation
Global Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Global Cancer Immunotherapy Market Dynamics

Driver
• Rising prevalence of cancer incidences

Restrain

• Increasing occurrence of immune-related adverse events

Opportunity

• Growing trend towards combination therapies

Market Players

Some of the major market players operating in the global cancer immunotherapy market are:

• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Janssen Pharmaceutical
• AstraZeneca
• Gilead Sciences, Inc.
• Eli Lilly and Company
• Amgen Inc.
• Novartis AG
• GSK
• Pfizer Inc.
• Incyte

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

Table of Contents

596 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Global Cancer Immunotherapy Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Product Type Segment Lifeline Curve
2.8 Market End User Coverage Grid
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestal Analysis
4.2 Porters 5 Forces
5 Global Cancer Immunotherapy Market: Regulations
6 Market Overview
6.1 Drivers
6.1.1 Rising Prevalence Of Cancer Incidences
6.1.2 Rising Technological Advancements
6.1.3 Increased Understanding Of Tumor Microenvironment
6.1.4 Rise In Patient Awareness And Demand For Targeted Treatment
6.2 Restraints
6.2.1 Increasing Occurrence Of Immune-related Adverse Events
6.2.2 Developing Resistance To Cancer Treatment
6.3 Opportunities
6.3.1 Growing Trend Towards Combination Therapies
6.3.2 Rising Integration Of Artificial Intelligence And Digital Health Tools
6.3.3 Development Of Next-generation Immunotherapies
6.4 Challenges
6.4.1 Lack Of Standardization In Biomarker Testing
6.4.2 Complexity Of Developing And Implementing Personalized Medicine
7 Global Cancer Immunotherapy Market, By Product Type
7.1 Overview
7.2 Checkpoint Inhibitors
7.2.1 Programmed Death 1 (Pd-1) & Programmed Death Ligand 1 (Pd-l1)
7.2.2 Cytotoxic T-lymphocyte-associated Protein-4 (Ctla-4)
7.3 Monoclonal Antibodies
7.3.1 Naked Monoclonal Antibodies
7.3.2 Conjugated Monoclonal Antibodies
7.3.3 Bispecific Monoclonal Antibodies
7.4 Vaccines
7.4.1 Prophylactic Vaccines
7.4.2 Therapeutic Vaccines
7.5 Cell Therapies
7.5.1 Chimeric Antigen Receptor (Car) T Cell Therapy
7.5.2 T Cell Therapy
7.6 Immunomodulators
7.6.1 Interferons
7.6.2 Interleukins
7.6.3 Granulocyte-macrophage Colony-stimulating Factor
7.7 Oncolytic Virus
8 Global Cancer Immunotherapy Market, By End User
8.1 Overview
8.2 Hospitals
8.3 Oncology Clinics
8.4 Homecare
8.5 Others
9 Global Cancer Immunotherapy Market, By Distribution Channel
9.1 Overview
9.2 Direct Tenders
9.3 Retail Sales
9.4 Pharmacies
9.4.1 Hospital
9.4.2 Retail
9.4.3 Online
10 Global Cancer Immunotherapy Market, By Form
10.1 Overview
10.2 Intravenous (Iv)
10.3 Intramuscular
10.4 Oral
11 Global Cancer Immunotherapy Market, By Application
11.1 Overview
11.2 Lung Cancer
11.2.1 Checkpoint Inhibitors
11.2.2 Monoclonal Antibodies
11.2.3 Cell Therapies
11.2.4 Immunomodulators
11.3 Breast Cancer
11.3.1 Checkpoint Inhibitors
11.3.2 Monoclonal Antibodies
11.3.3 Cell Therapies
11.3.4 Immunomodulators
11.4 Melanoma
11.4.1 Checkpoint Inhibitors
11.4.2 Monoclonal Antibodies
11.4.3 Cell Therapies
11.4.4 Immunomodulators
11.4.5 Oncolytic Virus
11.5 Multiple Myeloma
11.5.1 Checkpoint Inhibitors
11.5.2 Monoclonal Antibodies
11.5.3 Cell Therapies
11.5.4 Immunomodulators
11.6 Prostate Cancer
11.6.1 Checkpoint Inhibitors
11.6.2 Monoclonal Antibodies
11.6.3 Cell Therapies
11.6.4 Immunomodulators
11.6.5 Vaccines
11.7 Ovarian Cancer
11.7.1 Checkpoint Inhibitors
11.7.2 Monoclonal Antibodies
11.7.3 Cell Therapies
11.7.4 Immunomodulators
11.8 Cervical Cancer
11.8.1 Checkpoint Inhibitors
11.8.2 Monoclonal Antibodies
11.8.3 Vaccines
11.8.4 Cell Therapies
11.8.5 Immunomodulators
11.9 Stomach Cancer
11.9.1 Checkpoint Inhibitors
11.9.2 Monoclonal Antibodies
11.9.3 Cell Therapies
11.9.4 Immunomodulators
11.10 Colorectal Cancer
11.10.1 Checkpoint Inhibitors
11.10.2 Monoclonal Antibodies
11.10.3 Cell Therapies
11.10.4 Immunomodulators
11.11 Head And Neck Cancer
11.11.1 Checkpoint Inhibitors
11.11.2 Monoclonal Antibodies
11.11.3 Cell Therapies
11.11.4 Immunomodulators
11.12 Others
11.12.1 Checkpoint Inhibitors
11.12.2 Monoclonal Antibodies
11.12.3 Vaccines
11.12.4 Cell Therapies
11.12.5 Immunomodulators
12 Global Cancer Immunotherapy Market, By Region
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 Italy
12.3.4 Spain
12.3.5 U.K.
12.3.6 Switzerland
12.3.7 Netherlands
12.3.8 Russia
12.3.9 Turkey
12.3.10 Poland
12.3.11 Hungary
12.3.12 Lithuania
12.3.13 Austria
12.3.14 Ireland
12.3.15 Norway
12.3.16 Rest Of Europe
12.4 Asia-pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Australia
12.4.6 Singapore
12.4.7 Thailand
12.4.8 Indonesia
12.4.9 Philippines
12.4.10 Malaysia
12.4.11 Vietnam
12.4.12 Rest Of Asia-pacific
12.5 South America
12.5.1 Brazil
12.5.2 Argentina
12.5.3 Peru
12.5.4 Rest Of South America
12.6 Middle East And Africa
12.6.1 South Africa
12.6.2 Saudi Arabia
12.6.3 U.A.E.
12.6.4 Egypt
12.6.5 Israel
12.6.6 Oman
12.6.7 Qatar
12.6.8 Bahrain
12.6.9 Rest Of Middle East And Africa
13 Global Cancer Immunotherapy Market, Company Landscape
13.1 Company Share Analysis: Global
13.2 Company Share Analysis: North America
13.3 Company Share Analysis: Europe
13.4 Company Share Analysis: Asia-pacific
14 Swot Analysis
15 Company Profiles
15.1 Merck & Co., Inc.
15.1.1 Company Snapshot
15.1.2 Revenue Analysis
15.1.3 Company Share Analysis
15.1.4 Product Portfolio
15.1.5 Recent Developments
15.2 F. Hoffmann-la Roche Ltd
15.2.1 Company Snapshot
15.2.2 Revenue Analysis
15.2.3 Company Share Analysis
15.2.4 Product Portfolio
15.2.5 Recent Developments
15.3 Bristol-myers Squibb Company
15.3.1 Company Snapshot
15.3.2 Revenue Analysis
15.3.3 Company Share Analysis
15.3.4 Product Portfolio
15.3.5 Recent Developments
15.4 Janssen Global Services, Llc
15.4.1 Company Snapshot
15.4.2 Revenue Analysis
15.4.3 Company Share Analysis
15.4.4 Product Portfolio
15.4.5 Recent Developments
15.5 Astrazeneca
15.5.1 Company Snapshot
15.5.2 Revenue Analysis
15.5.3 Company Share Analysis
15.5.4 Product Portfolio
15.5.5 Recent Developments
15.6 Abbvie Inc.
15.6.1 Company Snapshot
15.6.2 Pipeline Portfolio
15.6.3 Recent Developments
15.7 Amgen Inc.
15.7.1 Company Snapshot
15.7.2 Revenue Analysis
15.7.3 Pipeline Portfolio
15.7.4 Product Portfolio
15.7.5 Recent Developments
15.8 Atara Biotherapeutics, Inc.
15.8.1 Company Snapshot
15.8.2 Pipeline Portfolio
15.8.3 Recent Developments
15.9 Bayer Ag
15.9.1 Company Snapshot
15.9.2 Pipeline Portfolio
15.9.3 Recent Developments
15.10 Celldex Therapeutics.
15.10.1 Company Snapshot
15.10.2 Pipeline Portfolio
15.10.3 Recent Developments
15.11 Cellectis
15.11.1 Company Snapshot
15.11.2 Pipeline Portfolio
15.11.3 Recent Developments
15.12 Gilead Sciences, Inc.
15.12.1 Company Snapshot
15.12.2 Revenue Analysis
15.12.3 Product Portfolio
15.12.4 Recent Developments
15.13 Gsk Plc.
15.13.1 Company Snapshot
15.13.2 Revenue Analysis
15.13.3 Product Portfolio
15.13.4 Recent Developments
15.14 Incyte.
15.14.1 Company Snapshot
15.14.2 Revenue Analysis
15.14.3 Product Portfolio
15.14.4 Recent Developments
15.15 Lilly.
15.15.1 Company Snapshot
15.15.2 Revenue Analysis
15.15.3 Product Portfolio
15.15.4 Recent Developments
15.16 Novartis Ag
15.16.1 Company Snapshot
15.16.2 Revenue Analysis
15.16.3 Pipeline Portfolio
15.16.4 Product Portfolio
15.16.5 Recent Developments
15.17 Pfizer Inc.
15.17.1 Company Snapshot
15.17.2 Revenue Analysis
15.17.3 Product Portfolio
15.17.4 Recent Developments
16 Questionnaire
17 Related Reports
List Of Tables
Table 1 Global Cancer Immunotherapy Market, By Product Type, 2022- 2031 (Usd Million)
Table 2 Global Checkpoint Inhibitors Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 3 Global Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 4 Global Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022- 2031 (Units)
Table 5 Global Monoclonal Antibodies In Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 6 Global Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 7 Global Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022- 2031 (Units)
Table 8 Global Vaccines In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 9 Global Vaccines In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 10 Global Vaccines In Cancer Immunotherapy Market, By Type, 2022- 2031 (Units)
Table 11 Global Cell Therapies In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 12 Global Cell Therapies In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 13 Global Cell Therapies In Cancer Immunotherapy Market, By Type, 2022- 2031 (Units)
Table 14 Global Immunomodulators In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 15 Global Immunomodulators In Cancer Immunotherapy Market, By Type, 2022- 2031 (Usd Million)
Table 16 Global Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 17 Global Oncolytic Virus In Cancer Immunotherapymarket, By Region, 2022-2031 (Usd Million)
Table 18 Global Cancer Immunotherapy Market, By End User, 2022- 2031 (Usd Million)
Table 19 Global Hospitals In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 20 Global Oncology Clinics In Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 21 Global Homecare In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 22 Global Others In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 23 Global Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 24 Global Direct Tenders In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 25 Global Retail Sales In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 26 Global Pharmacies In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 27 Global Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 28 Global Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 29 Global Intravenous In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 30 Global Intramuscular In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 31 Global Oral In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 32 Global Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 33 Global Lung Canceri N Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 34 Global Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 35 Global Breast Canceri N Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 36 Global Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 37 Global Melanoma In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 38 Global Melanoma Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 39 Global Multiple Myeloma In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 40 Global Multiple Myeloma Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 41 Global Prostate Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 42 Global Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 43 Global Ovarianc Ancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 44 Global Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 45 Global Cervical Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 46 Global Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 47 Global Stomach Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 48 Global Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 49 Global Colorectal Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 50 Global Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 51 Global Head And Neck Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 52 Global Head & Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 53 Global Others In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 54 Global Others Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 55 Global Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 56 North America Cancer Immunotherapy Market, By Country, 2022-2031 (Usd Million)
Table 57 North America Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 58 North America Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 59 North America Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 60 North America Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 61 North America Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 62 North America Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 63 North America Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 64 North America Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 65 North America Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 66 North America Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 67 North America Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 68 North America Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 69 North America Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 70 North America Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 71 North America Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 72 North America Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 73 North America Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 74 North America Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 75 North America Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 76 North America Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 77 North America Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 78 North America Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 79 North America Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 80 North America Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 81 North America Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 82 North America Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 83 North America Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 84 U.S. Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 85 U.S. Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 86 U.S. Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 87 U.S. Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 88 U.S. Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 89 U.S. Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 90 U.S. Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 91 U.S. Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 92 U.S. Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 93 U.S. Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 94 U.S. Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 95 U.S. Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 96 U.S. Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 97 U.S. Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 98 U.S. Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 99 U.S. Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 100 U.S. Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 101 U.S. Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 102 U.S. Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 103 U.S. Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 104 U.S. Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 105 U.S. Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 106 U.S. Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 107 U.S. Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 108 U.S. Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 109 U.S. Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 110 U.S. Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 111 U.S. Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 112 U.S. Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 113 U.S. Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 114 U.S. Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 115 U.S. Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 116 Canada Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 117 Canada Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 118 Canada Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 119 Canada Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 120 Canada Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 121 Canada Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 122 Canada Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 123 Canada Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 124 Canada Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 125 Canada Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 126 Canada Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 127 Canada Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 128 Canada Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 129 Canada Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 130 Canada Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 131 Canada Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 132 Canada Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 133 Canada Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 134 Canada Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 135 Canada Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 136 Canada Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 137 Canada Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 138 Canada Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 139 Canada Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 140 Canada Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 141 Canada Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 142 Canada Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 143 Canada Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 144 Canada Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 145 Canada Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 146 Canada Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 147 Canada Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 148 Mexico Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 149 Mexico Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
List Of Figures
Figure 1 Global Cancer Immunotherapy Market: Segmentation
Figure 2 Global Cancer Immunotherapy Market: Data Triangulation
Figure 3 Global Cancer Immunotherapy Market: Droc Analysis
Figure 4 Global Cancer Immunotherapy Market: Global Vs Regional Market Analysis
Figure 5 Global Cancer Immunotherapy Market: Company Research Analysis
Figure 6 Global Cancer Immunotherapy Market: Interview Demographics
Figure 7 Global Cancer Immunotherapy Market: Market End User Coverage Grid
Figure 8 Global Cancer Immunotherapy Market: Dbmr Market Position Grid
Figure 9 Global Cancer Immunotherapy Market: Vendor Share Analysis
Figure 10 Global Cancer Immunotherapy Market: Segmentation
Figure 11 Rising Prevalence Of Cancer And Rising Technological Advancements Are Expected To Drive The Growth Of The Global Cancer Immunotherapy Market From 2024 To 2034
Figure 12 Checkpoint Inhibitors Segment Is Expected To Account For The Largest Share Of The Global Cancer Chemotherapy Consumables Market In 2024 To 2031
Figure 13 North America Is Expected To Dominate The Global Cancer Immunotherapy Market And Asia-apcific Is Expected To Grow With The Highest Cagr In The Forecast Period Of 2024 To 2031
Figure 14 Asia-pacific Is The Fastest-growing Market For Global Cancer Immunotherapy Market Service Providers In The Forecast Period Of 2024 To 2031
Figure 15 Drivers, Restraints, Opportunities, And Challenges Of Global Cancer Immunotherapy Market
Figure 16 Global Cancer Immunotherapymarket : By Product Type, 2023
Figure 17 Global Cancer Immunotherapymarket : By Product Type, 2024-2031 (Usd Million)
Figure 18 Global Cancer Immunotherapymarket : By Product Type, Cagr (2024-2031)
Figure 19 Global Cancer Immunotherapymarket : By Product Type, Lifeline Curve
Figure 20 Global Cancer Immunotherapymarket : By End User, 2023
Figure 21 Global Cancer Immunotherapymarket : By End User, 2024-2031 (Usd Million)
Figure 22 Global Cancer Immunotherapymarket : By End User, Cagr (2024-2031)
Figure 23 Global Cancer Immunotherapymarket : By End User, Lifeline Curve
Figure 24 Global Cancer Immunotherapy Market: By Distribution Channel, 2023
Figure 25 Global Cancer Immunotherapy Market: By Distribution Channel, 2024-2031 (Usd Million)
Figure 26 Global Cancer Immunotherapy Market: By Distribution Channel, Cagr (2024-2031)
Figure 27 Global Cancer Immunotherapy Market: By Distribution Channel, Lifeline Curve
Figure 28 Global Cancer Immunotherapy Market: By Form, 2023
Figure 29 Global Cancer Immunotherapy Market: By Form, 2024-2031 (Usd Million)
Figure 30 Global Cancer Immunotherapy Market: By Form, Cagr (2024-2031)
Figure 31 Global Cancer Immunotherapy Market: By Form, Lifeline Curve
Figure 32 Global Cancer Immunotherapy Market: By Application, 2023
Figure 33 Global Cancer Immunotherapy Market: By Application, 2024-2031 (Usd Million)
Figure 34 Global Cancer Immunotherapy Market: By Application, Cagr (2024-2031)
Figure 35 Global Cancer Immunotherapy Market: By Application, Lifeline Curve
Figure 36 Global Cancer Immunotherapy Market: Snapshot (2023)
Figure 37 Global Cancer Immunotherapy Market: Company Share 2023 (%)
Figure 38 North America Cancer Immunotherapy Market: Company Share 2023 (%)
Figure 39 Europe Cancer Immunotherapy Market: Company Share 2023 (%)
Figure 40 Asia-pacific Cancer Immunotherapy Market: Company Share 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us